Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

SHA:688513 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue Revenue Growth	1,352	1,331	1,350	1,117	1,171	1,023
Revenue Growth	0.87%	-1.36%	20.82%	-4.56%	14.43%	10.96%
Gross Profit Gross Profit Growth	1,006	995.18	1,005	890.18	971.4	876.62
Operating Income Operating Income Growth	182.57	198.94	168.42	152.2	157.4	135.47
Net Income Net Income Growth	274.3	284.06	238.23	226.57	246.52	232.43
Earnings Per Share EPS Growth	1.58	1.63	1.36	1.28	1.39	1.32
EPS Growth	24.38%	19.85%	6.25%	-8.22%	5.68%	8.98%

Revenue by Geography

Chart

Fiscal Year	FY 2025
Period Ending	Dec 31, 2025
Southwest Region Southwest Region Growth	253.79
East China East China Growth	476.68
Northern China Northern China Growth	212.86
Southern China Southern China Growth	164.98
Northeast China Region Northeast China Region Growth	58.86
Northwestern Region Northwestern Region Growth	37.56
Central China Region Central China Region Growth	92.99
Overseas Regions Overseas Regions Growth	31.38
Total Total Growth	1,329

Cash & Debt

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Investments Cash & Investments Growth	1,622	1,613	1,424	1,523	1,347	1,505
Total Debt Total Debt Growth	81.33	146.65	114.04	223.48	105.29	20.02
Net Cash (Debt) Net Cash Growth	1,540	1,467	1,310	1,300	1,242	1,485
Net Cash Growth	14.09%	11.99%	0.78%	4.63%	-16.33%	-6.35%
Net Cash Per Share Net Cash Per Share Growth	8.88	8.42	7.48	7.34	7.03	8.43

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Operating Cash Flow Operating Cash Flow Growth	311.54	264.94	263.24	275.25	151.94	147.6
Capital Expenditures CapEx Growth	-91.08	-86.28	-117.42	-175.26	-339.33	-270.19
Free Cash Flow Free Cash Flow Growth	220.46	178.66	145.82	99.99	-187.38	-122.59
Free Cash Flow Growth	45.10%	22.52%	45.83%	-	-	-

Margins

Chart

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Gross Margin	74.40%	74.75%	74.42%	79.68%	82.99%	85.70%
Operating Margin	13.50%	14.94%	12.48%	13.62%	13.45%	13.24%
Pretax Margin	21.05%	22.51%	18.71%	21.63%	22.38%	24.14%
Profit Margin	20.29%	21.34%	17.65%	20.28%	21.06%	22.72%
FCF Margin	16.31%	13.42%	10.80%	8.95%	-16.01%	-11.98%

Dividends

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Dividend Per Share Dividend Per Share Growth	0.490	0.490	0.430	0.395	0.381	0.531
Dividend Per Share Growth	13.95%	13.95%	8.97%	3.57%	-28.19%	159.97%
Dividend Yield	1.10%	0.80%	1.46%	0.94%	0.96%	1.78%

Valuation

Chart

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug 2, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
PE Ratio	28.27	37.78	22.05	33.81	29.64	23.97
Forward PE	26.28	36.07	16.21	25.33	22.56	20.69
P/FCF Ratio	35.34	60.07	36.02	76.60	-	-
PS Ratio	5.76	8.06	3.89	6.86	6.24	5.45

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 30, 2026

Data Sources Report a data error